Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Celsentri
Maraviroc is a CCR5 co-receptor antagonist indicated for the treatment of HIV-1 infection in treatment-experienced adults, in combination with other antiretroviral agents, in patients with only CCR5-tropic HIV-1 detectable. It is classified as a chemokine receptor antagonist and works by blocking the CCR5 co-receptor on the surface of certain immune cells, preventing HIV-1 from entering these cells.
Used in combination with other antiretroviral medications to treat CCR5-tropic HIV-1 infection in treatment-experienced adults.
Outcome:
Reduced maraviroc levels
Mechanism:
Induction of CYP3A4
Outcome:
Increased maraviroc levels
Mechanism:
Inhibition of CYP3A4
Outcome:
Slightly reduced maraviroc absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Long-acting injectable (2025, 30% confidence)
Based on usage trends and clinical trial data, there is a low likelihood (5%) of significant label expansions in the near future.
Antiretroviral, CCR5 Antagonist
Piperidine derivative